BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Jung KS, Park JY, Chon YE, Kim H, Kang W, Kim BK, Kim SU, Kim DY, Han K, Ahn SH. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016;51:830-9. [DOI: 10.1007/s00535-015-1153-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
2 Park JY, Kim CW, Bae SH, Jung KS, Kim HY, Yoon SK, Han KH, Ahn SH. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int 2016;36:1108-15. [PMID: 26781724 DOI: 10.1111/liv.13059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
3 Lee S, Ahn SH, Jung KS, Kim DY, Kim BK, Kim SU, Baatarkhuu O, Ku HJ, Han K, Park JY. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. J Viral Hepat 2017;24:141-7. [DOI: 10.1111/jvh.12623] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
4 Kim DY, Lee HW, Song JE, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. J Med Virol 2018;90:497-502. [PMID: 29077211 DOI: 10.1002/jmv.24986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, Park JY, Kim DY, Han KH, Ahn SH. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat 2020;27:316-22. [PMID: 31639240 DOI: 10.1111/jvh.13222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
6 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kim MN, Park JY, Ahn SH, Kim BK, Kim SU, Kim DY, Han KH. Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. J Med Virol 2017;89:85-90. [PMID: 27357598 DOI: 10.1002/jmv.24616] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, Kim YS, Paik SK, Lee JI, Kim BK, Han KH, Ahn SH. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol 2019;17:1348-1355.e2. [PMID: 30613003 DOI: 10.1016/j.cgh.2018.10.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]